Monday, October 27, 2025
- 10:30AM-12:30PM
-
Abstract Number: 1019
Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
(1007–1037) Epidemiology & Public Health Poster II- 10:30AM-12:30PM
-
Abstract Number: 1100
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
(1088–1122) Immunological Complications of Medical Therapy Poster- 10:30AM-12:30PM
-
Abstract Number: 0958
Asynchronous Resolution of Inflammation and Fibrosis in A Prolonged Experimental Model Suggests Distinct Temporal Dynamics And Resolution Mechanisms in Systemic Sclerosis
(0955–0977) Systemic Sclerosis & Related Disorders – Basic Science Poster I- 10:30AM-12:30PM
-
Abstract Number: 1002
ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
(0978–1006) T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster- 10:30AM-12:30PM
-
Abstract Number: 1476
Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus: A Meta-Analysis of Prevalence and Clinical Correlates
(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II- 10:30AM-12:30PM
-
Abstract Number: 1374
AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
(1347–1375) Rheumatoid Arthritis – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1107
Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
(1088–1122) Immunological Complications of Medical Therapy Poster- 10:30AM-12:30PM
-
Abstract Number: 1108
Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
(1088–1122) Immunological Complications of Medical Therapy Poster- 10:30AM-12:30PM
-
Abstract Number: 1045
Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
(1038–1054) Health Services Research Poster II- 10:30AM-12:30PM
-
Abstract Number: 1533
Belimumab Is Associated with Early Improvement in Disease Activity Measures Among Patients with Systemic Lupus Erythematosus in the US
(1517–1552) Systemic Lupus Erythematosus – Treatment Poster II- 10:30AM-12:30PM
-
Abstract Number: 1209
Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II- 10:30AM-12:30PM
-
Abstract Number: 1241
Beyond Pain Severity in Psoriatic Arthritis: Pain Catastrophizing Independently Impacts Disease Burden and Quality of Life
(1221–1247) Pain in Rheumatic Disease Including Fibromyalgia Poster- 10:30AM-12:30PM
-
Abstract Number: 1400
Beyond the Glands: Hypogammaglobulinemia as a Clue to Peripheral Neuropathy in Sjogren´s Disease
(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes- 10:30AM-12:30PM
-
Abstract Number: 1449
Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies